Skip to main content

Alkermes plc.

ALKS
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001520262

In the last 90 days, Alkermes plc. insiders filed 0 open-market purchases and 8 sales; 425 institutions reported holding it in 13F filings for Q2 2026, worth $9.32B in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Alkermes plc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
8 filings
4 insiders, $4.24M in total
Insiders trading
4
Net value
−$4.24M
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Alkermes plc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Alkermes plc.
NameTitleLast reported holdingLast filingFilings, past year
Gaffin David JosephEVP, CLO, Alkermes, Inc.223,422Sep 3, 202611
Hopkinson Craig C.EVP R&D, Chief Medical Officer65,389Sep 1, 202618
Nichols Christian ToddSVP, Chief Commercial Officer102,193Aug 17, 20266
Jackson Blair CurtisPresident & CEO, Alkermes plc241,308Aug 7, 20266
snyderman nancy lynn MDDirector15,395Aug 3, 20262
Wright Christopher IDirector25,680Jun 12, 20262
Parisi Samuel JosephVP, Finance (Interim PAO)7,717May 29, 20265
McKeon Brian PDirector38,536May 22, 20261
Laurencin Cato TDirector33,769May 22, 20261
Lurker NancyDirector18,222May 22, 20262
Wilson Frank AndersDirector35,751May 22, 20261
Cooke ShaneDirector106,679May 22, 20262
Gaynor RichardDirector35,751May 22, 20261
Pops Richard FDirector and CEO, Alkermes plc1,377,740Mar 4, 20262
Reed JoshuaSVP, Chief Financial Officer–Mar 4, 20262
Brown Iain MichaelSVP, Chief Financial Officer148,196Feb 28, 20250
Alva Emily PetersonDirector27,302Jul 1, 20240
Daglio David Angelo Jr.Director27,780Jul 1, 20240
Landine Michael JSVP, Corp Dev., Alkermes, Inc.281,730Feb 27, 20240
Wysenski NancyDirector20,356Jul 10, 20230
Anstice David WDirector84,905Jun 16, 20220
Dixon Wendy LDirector53,124Jun 16, 20220

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Jul 2, 2021 (view filing)Jul 11 dayAnstice David WDirectorSSale−20.0K$24.58−$491.6K−21.5%73.1K after
Jul 30, 2021 (view filing)Jul 291 dayGaffin David JosephSVP, CLO, Alkermes, Inc.SSale−14.0K$26.00−$364.0K−15.8%74.6K after
Aug 4, 2021 (view filing)Aug 22 daysMcKeon Brian PDirectorPPurchase+10.0K$26.43+$264.3KNew position10.0K after
Aug 20, 2021 (view filing)Aug 191 dayBrown Iain MichaelSVP, Chief Financial OfficerSSale−40.0K$29.99−$1.20M−48.2%43.0K after
Aug 24, 2021 (view filing)Aug 231 dayAlva Emily PetersonDirectorPPurchase+1.65K$30.22+$49.9KNew position1.65K after
Feb 23, 2022 (view filing)Feb 185 daysHopkinson Craig C.EVP R&D, Chief Medical OfficerSSale−2.31K$25.17−$58.0K−19.5%9.50K after
Feb 24, 2022 (view filing)Feb 231 dayHopkinson Craig C.EVP R&D, Chief Medical OfficerSSale−12.0K$24.76−$296.7K−40.0%18.0K after
Mar 8, 2022 (view filing)Mar 44 dayssnyderman nancy lynn MDDirectorPPurchase+427$23.43+$10.0K+4.8%9.37K after
Apr 5, 2022 (view filing)Apr 41 dayCooke ShaneDirectorSSale−10.0K$28.18−$281.8K−10.0%90.5K after
Apr 12, 2022 (view filing)Apr 111 dayCooke ShaneDirectorSSale−10.0K$29.26−$292.6K−10.0%90.5K after
Apr 19, 2022 (view filing)Apr 181 dayCooke ShaneDirectorSSale−10.0K$28.88−$288.8K−10.0%90.5K after
Apr 22, 2022 (view filing)Apr 202 daysJackson Blair CurtisEVP, Chief Operating OfficerSSale−50.0K$29.61−$1.48M−36.3%87.9K after
Apr 27, 2022 (view filing)Apr 252 daysCooke ShaneDirectorSSale−10.0K$27.88−$278.8K−10.0%90.5K after
May 3, 2022 (view filing)May 21 dayCooke ShaneDirectorSSale−10.0K$29.23−$292.3K−10.0%90.5K after
May 3, 2022 (view filing)May 3Same dayLandine Michael JSVP, Corp Dev., Alkermes, Inc.SSale−25.0K$28.62−$715.5K−9.7%232.3K after
May 6, 2022 (view filing)May 5-61 dayPops Richard FDirector and CEO, Alkermes plcSSale−347.3K$27.98−$9.72M−26.4%968.3K after3 lots
May 12, 2022 (view filing)May 102 daysLandine Michael JSVP, Corp Dev., Alkermes, Inc.SSale−25.0K$27.22−$680.5K−9.7%232.3K after
May 19, 2022 (view filing)May 172 daysLandine Michael JSVP, Corp Dev., Alkermes, Inc.SSale−50.0K$29.15−$1.46M−17.7%232.3K after
Jun 21, 2022 (view filing)Jun 21Same dayNichols Christian ToddSVP, Chief Commercial OfficerSSale−7.47K$28.26−$211.2K−26.2%21.0K after
Nov 16, 2022 (view filing)Nov 142 daysDaglio David Angelo Jr.DirectorPPurchase+35.0K$23.31+$815.9K+77.8%80.0K after
May 10, 2023 (view filing)May 91 dayWysenski NancyDirectorSSale−41.3K$31.24−$1.29M−72.3%15.8K after10b5-1
May 30, 2023 (view filing)May 30Same dayNichols Christian ToddSVP, Chief Commercial OfficerSSale−27.1K$28.93−$785.0K−39.8%41.0K after10b5-1
Jun 7, 2023 (view filing)Jun 7Same dayLaurencin Cato TDirectorSSale−2.80K$31.50−$88.2K−27.2%7.48K after10b5-1
Jun 8, 2023 (view filing)Jun 8Same dayLaurencin Cato TDirectorSSale−2.64K$31.85−$84.0K−26.1%7.48K after10b5-1
Feb 16, 2024 (view filing)Feb 151 dayLaurencin Cato TDirectorSSale−2.69K$31.85−$85.7K−15.1%15.2K after10b5-1
Feb 27, 2024 (view filing)Feb 27Same dayParisi Samuel JosephVP, Finance (Interim PAO)SSale−2.56K$29.65−$75.9K−24.9%7.72K after
Mar 18, 2024 (view filing)Mar 18Same dayNichols Christian ToddSVP, Chief Commercial OfficerSSale−10.4K$28.10−$292.7K−13.6%65.9K after10b5-1
Nov 6, 2024 (view filing)Nov 6Same dayHopkinson Craig C.EVP R&D, Chief Medical OfficerSSale−10.5K$29.53−$309.2K−9.5%99.2K after10b5-1
Nov 12, 2024 (view filing)Nov 111 dayHopkinson Craig C.EVP R&D, Chief Medical OfficerSSale−59.0K$30.08−$1.77M−41.5%83.3K after10b5-1
Nov 27, 2024 (view filing)Nov 27Same dayNichols Christian ToddSVP, Chief Commercial OfficerSSale−5.21K$29.15−$151.8K−7.9%60.7K after10b5-1
Dec 4, 2024 (view filing)Dec 4Same dayHopkinson Craig C.EVP R&D, Chief Medical OfficerSSale−14.3K$30.77−$441.5K−17.2%69.0K after10b5-1
Dec 5, 2024 (view filing)Dec 5Same dayHopkinson Craig C.EVP R&D, Chief Medical OfficerSSale−9.22K$31.50−$290.5K−13.4%59.7K after10b5-1
Dec 9, 2024 (view filing)Dec 9Same dayLaurencin Cato TDirectorSSale−2.69K$31.85−$85.7K−10.5%23.0K after10b5-1
Dec 9, 2024 (view filing)Dec 9Same dayHopkinson Craig C.EVP R&D, Chief Medical OfficerSSale−61.2K$32.07−$1.96M−56.2%47.6K after10b5-1
Jan 31, 2025 (view filing)Jan 301 dayHopkinson Craig C.EVP R&D, Chief Medical OfficerSSale−100.9K$32.05−$3.23M−69.5%44.3K after10b5-1
Feb 14, 2025 (view filing)Feb 12-132 daysHopkinson Craig C.EVP R&D, Chief Medical OfficerSSale−349.3K$33.92−$11.8M−85.8%57.9K after4 lots10b5-1
Feb 20, 2025 (view filing)Feb 20Same dayParisi Samuel JosephVP, Finance (Interim PAO)SSale−1.33K$35.69−$47.4K−14.7%7.72K after10b5-1
Feb 25, 2025 (view filing)Feb 25Same dayParisi Samuel JosephVP, Finance (Interim PAO)SSale−3.74K$35.26−$132.0K−32.7%7.72K after10b5-1
Feb 28, 2025 (view filing)Feb 28Same dayParisi Samuel JosephVP, Finance (Interim PAO)SSale−1.94K$34.00−$65.9K−20.1%7.72K after10b5-1
Jun 10, 2025 (view filing)Jun 9-101 dayNichols Christian ToddSVP, Chief Commercial OfficerSSale−6.67K$31.52−$210.1K−7.2%86.2K after2 lots10b5-1
Oct 15, 2025 (view filing)Oct 15Same dayHopkinson Craig C.EVP R&D, Chief Medical OfficerSSale−9.00K$31.53−$283.8K−10.9%73.7K after10b5-1
Nov 3, 2025 (view filing)Nov 3Same dayHopkinson Craig C.EVP R&D, Chief Medical OfficerSSale−9.00K$30.38−$273.4K−11.4%69.7K after10b5-1
Dec 1, 2025 (view filing)Dec 1Same dayHopkinson Craig C.EVP R&D, Chief Medical OfficerSSale−4.00K$29.30−$117.2K−5.7%65.7K after10b5-1
Dec 5, 2025 (view filing)Dec 32 daysHopkinson Craig C.EVP R&D, Chief Medical OfficerSSale−3.75K$30.00−$112.4K−5.4%65.7K after10b5-1
Jan 2, 2026 (view filing)Jan 2Same dayHopkinson Craig C.EVP R&D, Chief Medical OfficerSSale−4.00K$28.00−$112.0K−6.1%61.7K after10b5-1
Jan 8, 2026 (view filing)Jan 8Same dayHopkinson Craig C.EVP R&D, Chief Medical OfficerSSale−5.00K$30.00−$150.0K−7.5%61.7K after10b5-1
Feb 2, 2026 (view filing)Feb 2Same dayCooke ShaneDirectorSSale−61.2K$34.57−$2.12M−37.1%103.7K after2 lots10b5-1
Feb 2, 2026 (view filing)Feb 2Same dayHopkinson Craig C.EVP R&D, Chief Medical OfficerSSale−9.00K$33.93−$305.4K−13.5%57.7K after2 lots10b5-1
Mar 4, 2026 (view filing)Mar 2-32 daysGaffin David JosephEVP, CLO, Alkermes, Inc.SSale−4.07K$29.53−$120.1K−1.7%235.6K after2 lots10b5-1
Mar 4, 2026 (view filing)Mar 22 daysHopkinson Craig C.EVP R&D, Chief Medical OfficerSSale−9.00K$29.72−$267.5K−9.1%89.4K after10b5-1